COLUMBIA, Md.--(BUSINESS WIRE)--Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced today the enrollment of its first patient in the Phase I/II open label, dose escalating DIGNITY trial to evaluate the safety and efficacy of ThermoDox with hyperthermia for the treatment of recurrent chest wall (RCW) breast cancer, an aggressive form of cancer with a poor prognosis and limited treatment options. The first patient treated in the DIGNITY trial was at Rhode Island Hospital by Principal Investigator Brigid O’Connor, MD. The other clinical sites participating in the trial include: the Florida Cancer Institute in Hudson, FL led by Principal Investigator Arthur Maztkowitz, MD; the New York University Hospital in New York, NY led by Silvia Formenti, MD; and the Cancer Treatment Center of America in Tulsa, OK led by Petra Ketterl, MD.
